Title:Targeted Mitochondrial Drugs for Treatment of Ischemia-Reperfusion
Injury
Volume: 23
Issue: 16
Author(s): Jin-Fu Peng, Oluwabukunmi Modupe Salami, Olive Habimana, Yu-Xin Xie, Hui Yao and Guang-Hui Yi*
Affiliation:
- Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, University of South China, Hengyang, Hunan, 421001, China
Keywords:
Ischemia-reperfusion injury, targeted mitochondrial drugs, mitochondrial dysfunction, mitochondrial membrane, drug targets, reactive oxygen species.
Abstract: Ischemia-reperfusion injury is a complex hemodynamic pathology that is a leading cause
of death worldwide and occurs in many body organs. Numerous studies have shown that mitochondria
play an important role in the occurrence mechanism of ischemia-reperfusion injury and that mitochondrial
structural abnormalities and dysfunction lead to the disruption of the homeostasis of the
whole mitochondria. At this time, mitochondria are not just sub-organelles to produce ATP but also
important targets for regulating ischemia-reperfusion injury; therefore, drugs targeting mitochondria
can serve as a new strategy to treat ischemia-reperfusion injury. Based on this view, in this review,
we discuss potential therapeutic agents for both mitochondrial structural abnormalities and mitochondrial
dysfunction, highlighting the application and prospects of targeted mitochondrial drugs in
the treatment of ischemia-reperfusion injury, and try to provide new ideas for the clinical treatment
of the ischemia-reperfusion injury.